Scientists have been searching for ways to cure DMD for as long as they have known about the disease. Today, based on the wealth of knowledge about the underlying genetic and molecular mechanisms ...

Entrada Therapeutics is finally able to get its Duchenne muscular dystrophy candidate (DMD) back on track after the FDA lifted a more than two-year-long hold. Dubbed ENTR-601-44, the endosomal ...

Santhera has reached an agreement with health insurance funds in Germany on reimbursement of its Agamree treatment for Duchenne muscular dystrophy (DMD) that should support broad use of the drug.

The company has previously said that it sees deramiocel as an add-on therapy to current chronic treatments for DMD, including corticosteroids and exon-skipping therapies. Deramiocel is approaching ...